[Severely burned patients after surgery: recombinant human growth hormone therapy its metabolic effects].

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

To observe the effect of recombinant human growth hormone on metabolism in severely burned patients.

Who Took Part

The study group was 2001, patients.

The age groups tagged for this paper are children, teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

The excised burn wounds were closed with microautograft and allograft skin.

Blood samples were collected at 6:00 am for assaying of growth hormone, blood glucose, blood insulin, anti-insulin antibody, glucagon, cortisol, serum amino acid profile, transferring, proalbumin, total protein, dielectric, and resting energy expenditure (REE) was also measured.

What Was Measured

The subject headings attached to it are Amino Acids, Burns, Growth Hormone, Human Growth Hormone, Insulin, Recombinant Proteins and Sodium Chloride.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 2001, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Zhonghua wai ke za zhi [Chinese journal of surgery]), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.